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1. Introduction 
The study of in vivo bioscience and medical treatment from molecular point of view requires 
the precise evaluation of molecule behavior in living systems, especially involving the 
human body. Positron emission tomography (PET) is a non–invasive imaging technology 
with a good resolution, high sensitivity, and accurate quantification, which makes it 
possible to timely and spatially analyze the dynamic behavior of molecules in in vivo 
systems using a specific molecular probe labeled with positron–emitting radionuclides such 
as 11C, 13N, 18F, and 76Br (Phelps, 2004). PET has been extensively used for the diagnosis of 
diseases such as cancers, cerebral dysfunction, and etc., and recently, in medical checkups as 
an early detection approach. In the current paradigm shift to drug discovery, PET molecular 
imaging will provide an important new scientific platform to execute human microdosing 
trials during the early stage of drug development, especially from the viewpoint of 
promoting evidence–based medicine (Lappin & Garner, 2003; Bergström et al., 2003). A core 
concept and the driving force of molecular imaging would truly be “Seeing is Believing”. It 
is of significant value to unveil the vital functions and phenomena of living systems by 
molecular imaging the in vivo behavior of a ligand and the localization of a biologically 
significant target molecule. The potential of PET molecular imaging in an interdisciplinary 
scientific area strongly depends on the availability of suitable radioactive molecular probes 
with specific biological functions. The development of biologically significant novel PET 
probes will be accomplished by the combination of an efficient synthetic strategy for 
designed molecules and new advances in the field of labeling chemistry (Schubiger et al., 
2007). 
Among the short–lived positron–emitting radionuclides, 11C and 18F with a half–life of 20.4 
and 109.8 min, respectively, have often been used for radiolabeling as the most significant 
radionuclides from both a chemical and biological perspective as well as from the viewpoint 
www.intechopen.com
 Positron Emission Tomography – Current Clinical and Research Aspects 116 
of radiation exposure safety. With respect to the 11C–incorporation on organic carbon 
frameworks, we have been developing multiple–type Pd0–mediated rapid [11C]methylations 
onto an arene including a heteroaromatic compound, and alkene, alkyne and alkane 
structures by [11C]carbon–carbon bond forming reactions (rapid C–[11C]methylations) using 
[11C]methyl iodide and an excess amount of an organostannane or organoboron within a 
very short time span (5 min) (Suzuki et al., 1997; Hosoya et al., 2004; Hosoya et al., 2006; Doi 
et al., 2009; Suzuki et al., 2009). These labeling reactions provide a high generality and 
practicability as groundbreaking methods for introducing the [11C]methyl group into almost 
any organic framework. Regarding the 18F radionuclide, a rather longer half–lived positron 
emitter than 11C, the 18F–labeling can be mainly accomplished by ordinary methods 
involving nucleophile substitution with the 18F anion, as exemplified by the synthesis of 2-
[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) (Ido et al., 1978) and 3’-[18F]fluoro-3’-
deoxythymidine ([18F]FLT) (Grierson et al, 1997, as cited in Bading & Shields, 2008). In this 
chapter, newly advanced methodologies for introducing the short–lived 11C radionuclide 
into various carbon frameworks (rapid C–[11C]methylations) and the rather longer half–
lived 18F radionuclide into a benzene framework (C–[18F]fluoromethylation) are described in 
detail in addition to their applications for radiolabeling biologically and clinically significant 
organic molecules.  
2. PET molecular imaging technology–principle, properties, and benefits 
The short–lived positron emitting radionuclide 11C was first produced by Crane and 
Lauritsen in 1934 (Lauritsen et al., 1934, as cited in Allard et al., 2008). They investigated the 
physical properties of this radionuclide and demonstrated that 11C undergoes + decay with 
a half–life of 20.4 min, yielding 11B as the stable nuclide (Figure 1). A positron (positively 
charged electron, e+) ejected by this process collides with a nearby electron within a few 
millimeters in tissue to produce two high–energy –ray photons of 511 keV each. These 
photons travel in opposite directions at 180 degrees, penetrating the body, and can be 
detected by a pair of opposing scintillation detectors. If the two opposite detectors are 
simultaneously hit, it is assumed that the photons come from the same decay event. The 
data are fed to a computer system that can reconstruct the three–dimensional tomographic 
imaging and provide a highly accurate quantitative analysis of a radiolabeled drug in a 
body over time, measured as becquerel (Bq) per pixel. Because of the really high specific 
radioactivity of positron–emitter labeled compounds, PET enables in vivo imaging using an 
extremely small mass of the compound (sub–femtomole), namely, at extremely low 
concentrations (sub–picomolar) far below the critical concentration of pharmacological 
effects. The other typical positron–emitting radionuclides for PET studies, along with their 
half–lives (t1/2) are: 15O (t1/2 = 2.07 min); 13N (t1/2 = 9.96 min); 68Ga (t1/2 = 67.6 min); 18F (t1/2 = 
109.7 min); 64Cu (t1/2 = 12.7 h). The benefits of the use of PET technology in scientific 
research areas are as follows: (1) O, N, and C are included as ubiquitous elements 
constituting a biologically active compound in nature, providing the diversity of the labeled 
compounds without modifying the properties (or functions) of the molecule; (2) the 
molecule including the positron emitting radionuclide can be externally and quantitatively 
measured using a PET camera with a high resolution and sensitivity; (3) a short half–life is 
very relevant to human PET studies in terms of the high required safety for radiation 
exposure. 
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Fig. 1. Principle of the brain imaging by PET as shown by 11C to 11B decay. 
3. Rapid chemistry needed for 11C–labeling–working against time 
The special aspects of PET radiochemistry such as short half–lives, extremely small amounts 
of available radionuclides, and relatively high–energy radiation impose severe restrictions 
on the synthesis of PET probes. In general, the synthesis of a pure, injectable 11C–labeled 
probe must be accomplished within 2–half lives of ca. 40 min due to the quick decay of the 
radioactivity. The synthesis process for the pharmaceutical formulation includes the 
following steps: (1) derivatives of a 11C isotope produced by a cyclotoron to an appropriate 
labeling precursor such as 11CH4, 11CH3I, 11CH3OTf, 11CO, and 11CO2; (2) evaluation of the 
reaction efficiency (radiochemical yield) by analytical high performance liquid 
chromatography (HPLC) after the 11C–labeling of the target probe; (3) work–up and 
chromatographic purification of the desired 11C–labeled probe; and (4) preparation of an 
injectable solution for an animal/human PET study (pharmaceutical formulation). 
Therefore, the time allowed for a 11C–labeling reaction should be less than 5 min, inevitably 
necessitating a rapid chemical reaction. Another difficulty encountered in the synthesis of a 
11C–labeled PET probe is the availability of an extremely small amount (nano–mol level) of 
the 11C–labeling precursor such as [11C]CH3I. Therefore, the labeling reaction is usually 
carried out with a large amount (milli–gram level) of the reacting substrate to promote the 
reaction. In addition, the efficient and secure purification of a small amount of the 
synthesized 11C–labeled probe from a large amount of the remaining substrate must be 
considered since a PET probe is usually intravenously injected into both living animals and 
humans.  
4. Attractive features of rapid C–[11C]methylation–four kinds of rapid  
C–[11C]methylations 
Thus far, in the field of PET chemistry, the [11C]methylation of the hetero atoms of N, O, and 
S has mainly been explored and utilized because of its simple reaction conditions namely, 
only by mixing 11CH3I and a large amount of the substrate (Allard et al., 2008). However, a 
carbon–hetero atom bond tends to be readily metabolized to produce 11CH3OH, 11CH2O and 
H11COOH, which are dispersed in whole organs, thus decreasing the credibility of a PET 
image. It could be said that “the facts are the enemy of the truth.” We here considered that 
the [11C]methylation by [11C]C–C bond formation (referred to as C–[11C]methylation) 
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180°
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(Suzuki et al., 1997) will have a number of benefits because of the following reasons: (1) The 
[11C]methyl group introduced into a carbon will be metabolically stable, and therefore, such 
a 11C–labeled probe will provide a highly credible PET image; (2) the methyl group is the 
smallest nonpolar functional group, and therefore, the introduction of a methyl group has 
the least influence on the biological activity of the parent compound; furthermore, the 
methyl group is rather positively used in drug design as magic methyl to control the 
lipophilicity as well as the fixation of the conformation of a molecule; (3) a short half–life of 
the 11C–incorporated probe is favorable for the rapid screening involving optimization of 
reaction conditions and the evaluation of the in vivo behavior, thus allowing several trials 
per day. Accordingly, we have devised a plan to realize four types of rapid C–
[11C]methylations for arene, alkene, alkyne, and alkane frameworks (Figure 2), which allow 
the 11C–labeling of almost any organic compound. The following pharmacokinetic 
(PK)/pharmacodynamic (PD) studies in in vivo systems by PET provide a key methodology 
to eventually promote “evidence–based medicine” at the molecular level. With regard to 
such a [11C]C–C bond forming reaction, organometallic compounds comprised of the group 
IA and IIA metals were previously used. For example, [methyl–11C]thymidine was prepared 
in a radiochemical yield of 20% with radiochemical purities >99% by the reaction of 
[11C]CH3I with the lithiated derivative obtained from the bromo precursor (Sundoro-Wu et 
al., 1984). In such a reaction, however, the use of a moisture–sensitive organolithium 
compound is difficult to justify the stoichiometry for an extremely small amount of 
[11C]CH3I, resulting in the inevitable production of a large amount of an undesired 
demethylated derivative due to the use of an excess amount of the lithiated substrate. 
Furthermore, the undesired side reaction such as the rearrangement of the lithiation position 
occurs under such drastic conditions. Consequently, the tedious separation of demethylated 
side products and regioisomers is inevitably needed to purify the desired compound. Thus, 
the reaction based on the use of “soft metalloids” as nucleophilic substrates was ideal for 
this requirement, if realized, as described in detail in section 5. 
 
Fig. 2. Attractive features of rapid C–[11C]methylations. 
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5. Benefits of using of an organostannane as a trapping substrate for 
[11C]methyl Iodide 
A general protocol for the rapid C–methylation was established for the first time based on a 
Stille–type reaction using phenyltributylstannane and CH3I, then [11C]CH3I, a frequently–
used 11C–labeling precursor (Suzuki et al., 1997). The Stille reaction is among the most 
generally used C–C bond forming reactions in organic synthesis as a reaction of an 
organometallic (–metaloid) reagent with an organic electrophile (Stille, 1986). The organotin 
compounds can be prepared by a number of routes even if containing a variety of reactive 
functional groups. Moreover, the reagent is not particularly oxygen or moisture sensitive. In 
the palladium(0)–catalyzed coupling of an organic electrophile with an organotin reagent, 
essentially only one of the groups on the tin atom selectively enters into the coupling 
reaction, namely an unsymmetrical organotin reagent comprised of three simple alkyl 
(except methyl) groups, and the fourth group, such as the arenyl, alkenyl, or alkynyl group. 
The latter fourth group can selectively transfer. The Stille reaction was thought to be useful 
for our purpose because of its favorable properties of the triorganostannane compounds, 
such as (1) their high tolerance to various chemical reactions and chromatographic 
purification conditions, enabling the incorporation of a radioisotope as the final step of the 
PET–probe synthesis; and (2) the extremely low polarity of a trialkyltin(IV) derivative, 
enabling an easy separation of the desired product from a large amount of the remaining tin 
substrate. However, to the best of our knowledge, at that time, there was little information 
on the Stille reaction using methyl iodide as an sp3–hybridized carbon partner in 
comparison to its wide applicability to sp2–hybridized arenyl or sp3–hybridized allylic 
halides; it seemed rather difficult to realize the methylation in high yield due to the 
unavoidable scrambling between the methyl group in methyl iodide and phenyl groups in 
the triphenylphosphine ligand, P(C6H5)3, by the reaction of methyl iodide with the less 
reactive phenyltributylstannane in the presence of Pd{P(C6H5)3}4 (Morita et al., 1995). The 
use of the higher reactive phenyltrimethylsytannane as a substrate also induces the 
competition between 11CH3 in 11CH3I and CH3 groups in the stannane to produce 
[11C]ethane as a byproduct (Suzuki et al., 1997, also see section 6). Furthermore, the labeled–
compound obtained from the trimethyltin derivative resulted in a much lower specific 
activity than the tributyltin derivative (Samuelsson & Långström, 2003; Madsen et al., 2003). 
It should be added that tributyltin derivative is practically non-toxic, while the trimethyl- 
and triethyltins have a significant acute toxicity (Smith, 1998; Buck et al., 2003). 
Consequently, we have been obliged to devise new reaction conditions capable of 
promoting a rapid cross–coupling reaction using the less reactive tributyltin derivative as a 
substrate for trapping [11C]CH3I.  
6. Realization of Pd0–mediated rapid C–methylations by the reaction of 
methyl iodide with an excess amount of arenyltributylstannanes (rapid 
coupling between sp2(arenyl)– and sp3–hybridized carbons) 
Keeping the 11C radiolabeling conditions of a PET–probe synthesis in mind, we set up a 
model reaction using methyl iodide and an excess amount of phenyltributylstannane (1) 
(CH3I/1 = 1:40 in molar ratio) to possibly restrict the reaction time to less than 5 min (Table 
1) (Suzuki et al., 1997). The yield of the methylated product, toluene (2), was determined on 
the basis of the CH3I consumption. As anticipated, the conventional Stille–reaction 
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conditions with a reaction time of 30 min did not give the desired product at all (Table 1, 
Entry 1), leading us to introduce the concept of coordinative unsaturation to activate the 
palladium catalyst. Thus, we found that the use of a coordinatively unsaturated Pd0 
complex, Pd{P(o-CH3C6H4)3}2 (Paul et al., 1995), generated in situ by mixing Pd2(dba)3 (dba: 
dibenzylideneacetone) and the sterically bulky tri-o-tolylphosphine (P(o-CH3C6H4)3; cone 
angle, 194°) (Tolman, 1977) instead of triphenylphosphine (P(C6H5)3; cone angle 145°) 
(Tolman, 1977), significantly increased the coupling efficiency (76%, Table 1, Entry 2). Next, 
we introduced an additional concept to shorten the reaction time (from 30 min to 5 min); the 
simple heating (80 °C) was less effective for lowering the yield, but the stabilization of the 
transiently formed palladium catalyst, strongly solvated by N,N-dimethylformamide (DMF), 
effectively suppressed the decrease in the yield to a considerable extent. Furthermore, we 
intended to enhance the reactivity by adding a CuI salt with the expectation of Sn to Cu 
transmetallation, and K2CO3 in order to react with the (n-C4H9)3SnX (X = I and/or Cl) 
generated during the reaction to neutralize the reaction system. Thus, the reaction using the 
CH3I/1/Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 system (1:40:0.5:2:2:2) in DMF at 60 °C for 5 
min gave the desired product in 91% yield (Table 1, Entry 6) (Suzuki et al., 1997). It should be 
noted that when phenyltrimethylstannane was used instead of phenyltributylstannane, the 
reaction produced toluene (2) in >100% yield (122–129%) together with ethane, indicating 
the unexpected cross–coupling reactions (scrambling) between the methyl in methyl iodide 
and the methyl on the tin atom. The reaction between the phenyl and methyl on the tin atom 
was also contaminated to yield toluene (undesired product in actual PET probe synthesis) to 
a significant extent (Suzuki et al., 1997), thereby decreasing the yield of the desired 
[11C]toluene. The specific radioactivity of desired [11C]toluene would also be deduced by 
the contamination of [12C]toluene formed by the reaction between the methyl 
 
 
Entrya Pd0 comlex Ligand (L) and/or 
additive (μmol) 
Pd0:L Solvent Temp. Time Yield of 2 
 (μmol) (mol ratio)  (°C) (min) (%)a 
1 Pd{P(C6H5)3}4 
(10) 
— — DMSO 40 30 0 
2 Pd2(dba)3 (5) P(o-CH3C6H4)3 (20) 1:2 DME 40 30 76 
3 Pd2(dba)3 (5) P(o-CH3C6H4)3 (20) 1:2 DME 80 5 41 
4 Pd2(dba)3 (5) P(o-CH3C6H4)3 (20) 1:2 DMF 80 5 63 
5 Pd2(dba)3 (5) P(o-CH3C6H4)3 (20), 
CuI (20) 
1:2 DMF 60 5 3 
6 Pd2(dba)3 (5) P(o-CH3C6H4)3 (20), 
CuCl (20), K2CO3 (20)
1:2 DMF 60 5 91 
aReaction was carried out with CH3I (10 mol), stannane 1 (400 mol), and Pd0 (10 mol). bYield was 
determied by GLC analysis based on CH3I consumption. dba: dibenzylideneacetone; DMSO: dimethyl 
sulfoxide; DME: 1,2-dimethoxyethane; DMF: N,N-dimethylformamide. 
Table 1. Rapid cross–coupling of methyl iodide and phenyltributylstannane (1). 
CH3I +
Sn(n-C4H9)3
Pd0 catalyst
Additive
Solvent (1 mL)
CH3
1 2
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groups and phenyl groups on the tin atom (Madsen et al., 2003). It was assumed from these 
results that the reaction of [11C]CH3I and phenyltrimethylstannane under PET radiolabeling 
conditions would produce the undesired radioactive and volatile [11C]ethane. As described 
later (see the section 8.2), these phenomena were observed during the palladium–mediated 
reaction of 1-(2’-Deoxy-2’-fluoro--D-arabinofuranosyl)-5-(trimethylstannyl)uracil to 
synthesize 1-(2’-Deoxy-2’-fluoro--D-arabinofuranosyl)-[methyl–11C]thymidine (Samuelsson 
& Långström, 2003). Therefore, we concluded that the arenyltributylstannane, though less 
reactive, would be a much more suitable coupling partner than the arenyltrimethylstannane 
in view of the increased efficiency of the reaction, relatively low toxicity, and the safety of 
the radiation exposure. 
The conditions of the reaction are significantly different from those of the originally 
reported Stille coupling reaction. Thus, the coupling of methyl iodide and 
phenyltributylstannane probably proceeds by the mechanism proposed in Equations 1–5 
(Suzuki et al., 1997). In the first step, methyl iodide undergoes oxidative addition with 
   
a Pd0 species to generate methyl–PdII iodide 3 (oxidative addition, Eq. (1)). The PdII complex 
3 may directly react with the phenylstannane 1 to afford the (methyl)(phenyl)PdII complex 6 
(substitution, Eq. (4)); however, the formation of the latter would be facilitated by the 
phenyl–copper compound 4 formed by the preceding Sn/Cu transmetallation (Eq. (2)). The 
effect of K2CO3 would be explained by the neutralization of (n-C4H9)3SnX to form the stable 
bis(tributylstannyl)carbonate 5 (Eq. (3)). At the same time, K2CO3 serves to synergically 
work with a CuI salt to promote the Sn/Cu transmetallation (Eqs. (2) and (3)) (Hosoya et al., 
2006). Finally, toluene is formed by reductive elimination from the PdII complex 6 (reductive 
elimination, Eq. (5)). The significant ligand effect of tri-o-tolylphosphine is attributed to its 
considerable bulkiness (cone angle = 194°, which is greater than that in tri-tert-
butylphosphine (182°)) (Tolman, 1997), which facilitates the generation of the coordinatively 
unsaturated Pd0 and PdII intermediates (Louie & Hartwig, 1995). Transmetallation to give 6 
and/or the reductive elimination of toluene requires the formation of the tricoordinate PdII 
complex. DMF may stabilize such Pd intermediates even at high temperatures. It should be 
noted that J. K. Stille et al. previously reported the reaction of methyl iodide and p-
methoxyphenyltributylstannane in the presence of Pd{P(C6H5)3}4 at 50 °C for 24 h, in which 
the scrambling reaction between the methyl and the phenyl groups in the methyl iodide and 
triphenylphosphines, respectively, preferably occurred to give the desired p-
methoxytoluene in only 3% together with 1-methoxy-4-phenylbenzene as the major 
CH3I+ [Pd{P(o-CH3C6H4)3}2]
+ CuX
+
+ [Pd{P(o-CH3C6H4)3}]
[Pd(CH3)I{P(o-CH3C6H4)3}]
3
1
6
toluene (2)
[Pd(CH3)(C6H5){P(o-CH3C6H4)3}]
6
CH3–C6H5
P(o-CH3C6H4)3
C6H5Sn(n-C4H9)3 + P(o-CH3C6H4)3 [Cu(C6H5){P(o-CH3C6H4)3}] (n-C4H9)3SnX
[(n-C4H9)3SnO]2C=OK2CO3
+
X = Cl or Br; M = (n-C4H9)3Sn or Cu{P(o-CH3C6H4)3}n.
3 + C6H5M +MI
4
5
2 (n-C4H9)3SnX + + 2 KX
(1)
(2)
(4)
(5)
(3)
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byproduct in 8% yield, suggesting that the promotion of the Stille reaction using methyl 
iodide as an sp3–carbon partner could be difficult (Morita et al., 1995) until our successful 
result was demonstrated (Suzuki et al., 1997).  
7. Application for the synthesis of 15R-[11C]TIC methyl ester as specific probe 
for prostaglandin receptor (IP2) in the central nervous system 
In a preceding study of prostaglangin (PG), we succeeded in developing (15R)-16-m-tolyl-
17,18,19,20-tetranorisocarbacyclin (15R-TIC, 7), which was selectively responsive to a novel 
prostacyclin receptor (IP2) in the central nervous system (Suzuki et al., 1996; Suzuki et al., 
2000b). The tolyl group in 7 was intended as a trigger component to create a PET molecular 
probe. Therefore, we planned to apply the rapid C–methylation conditions to the synthesis 
of a PET molecular probe, the 15R-[11C]TIC methyl ester using [11C]CH3I, prepared from 
[11C]CO2 according to an established method (Fowler & Wolf, 1997), and the stannane 8 
(Suzuki et al., 2000a). However, we found that the C–[11C]methylation under radiolabeling 
conditions, even after using an excess amount of a CuI salt, lacked reproducibility for some 
unknown reasons. During the course to overcome this difficulty along with the actual PET–
probe synthesis, we encountered some valuable information that led to a solution of the 
problem by using CuI instead of CuCl that severely retarded the methylation of the 
phenyltributylstannane (Table 1, Entry 5). In order to minimize this inhibitory effect of CuI, 
we changed the one–pot operation to a two–pot stepwise procedure during the actual PET–
probe synthesis (Figure 3) (Suzuki et al., 2004). This procedure consists of independent 
syntheses of a methylpalladium complex and a phenyl copper complex at room temperature 
(25 °C), and then the mixing of these species in one portion at a higher temperature (65 °C, 5 
min). As expected, the highly qualified PET probe, the 15R-TIC methyl ester ([11C]9), was 
obtained by thus C–[11C]methylation procedure from 8 in an 85% isolated yield (decay–
corrected, based on the radioactivity of [11C]CH3I trapped in the Pd solution; it indicates the 
production efficiency) with a purity of greater than 98%, which was applicable for a human 
PET study with a sufficient radioactivity of 2–3 GBq and high reproducibility (Figure 3). The 
specific radioactivity was 37–100 GBq mol–1. The total synthesis time was 35–40 min. 
After the ethical committee gave its official approval for a human PET study, the principal 
author, M. Suzuki, was nominated to be the first volunteer. Thus, the 15R-[11C]TIC methyl 
ester ([11C]9) was injected into his right arm and it passed through the blood–brain barrier. It 
was then hydrolyzed in the brain to a free carboxylic acid, which was eventually bound to 
the IP2 receptor. PET images of horizontal slices indicated that a new receptor, IP2, was 
distributed throughout various structures in the human brain (Figure 4) (Suzuki et al., 2004).  
A PET study of the middle cerebral artery occlusion using a monkey model demonstrated 
that 15R-TIC revealed a potent neuroprotective effect against focal cerebral ischemia as 
judged by the [15O]O2 consumption and the uptake of [18F]FDG (Cui et al., 2006). Recently, 
rat PET studies using the 15R-[11C]TIC methyl ester ([11C]9) showed that [11C]9 could be 
useful for the in vivo analyses of the mrp2–mediated hepatobiliary transport (Takashima et 
al., 2010). Furthermore, the PK/PD studies of [11C]9 in humans (submitted for publication) 
as well as a translational study of Alzheimer’s disease patients to evaluate the progress of 
such neurodegenerative diseases are now in progress. A PET probe of the 17-(3-
[11C]methylphenyl)-18,19,20-trinor-prostaglandin F2 isopropyl ester ([11C]10) (Björkman et 
al., 2000) targeting the receptor of prostaglandin F2 (PGF2) was also synthesized using a 
procedure similar to [11C]9.  
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[11C]CH3I, formed from [11C]CO2 according to the established method, was trapped in a solution of 
Pd2(dba)3 (1.3 mg, 1.4 µmol) and P(o-CH3C6H4)3 (1.7 mg, 5.6 µmol) in DMF (230 µL) at room 
temperature. The solution was transferred to a vial containing stannyl precursor 8 (2.0 mg, 3.0 µmol), 
CuCl (1.5 mg, 15µmol), and K2CO3 (2.1 mg, 15 µmol) in DMF (80 µL), and the resulting mixture was 
heated at 65 °C for 5 min. Prior to the preparative HPLC, a solid phase extraction column was used to 
remove the salts and palladium residue from the reaction mixture. The desired product, 15R-[11C]TIC 
methyl ester [11C]9, after HPLC separation and intravenous formulation usually had a isolated 
radioactivity of approximately 2.5 GBq, sufficient for an in vivo human PET study. 
Fig. 3. Synthesis of 15R–[11C]TIC methyl ester ([11C]9) under PET radiolabeling conditions.  
HO HO H
COOR
X
7: R
 
= H, X = CH3, 15R-TIC
8: R = CH3, X = (n-C4H9)3Sn
[11C]9: R = CH3, X = 11CH3
HO
HO
COOCH(CH3)2
OH
11CH3
[11C]10
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Fig. 4. PET imaging in human brain using [11C]9. 
8. Rapid C–[11C]methylation of heteroaromatic compounds: importance of 
using a large amount of bulky arenylphosphine, CuI/F– or CuI/K2CO3 synergic 
effect, and the selection of an amide solvent 
8.1 Pd0–mediated rapid coupling of methyl iodide and heteroarenylstannanes 
applicable to 2- and 3-[11C]methylpyridines 
There is a strong demand for the incorporation of a short–lived 11C–labeled methyl group 
into the heteroaromatic carbon frameworks, because such structures often appear in major 
drugs and their promising candidates. The Pd0–mediated rapid trapping of methyl iodide 
with an excess amount of a hetero–aromatic ring–substituted tributylstannane 11a–i was 
done (Suzuki et al., 2009) by first using our previously developed CH3I/11a–
i/Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 (1:40:0.5:2:2:2) combination system in DMF at 60 
°C for 5 min (conditions A; Suzuki et al., 1997), but the reaction produced low yields of the 
various kinds of heteroaromatic compounds (Table 2, Entries 1–9). An increase in the 
phosphine ligand (conditions B) significantly improved the yield for the heteroarenyl 
stannanes, 11b, 11c, and 11i, but the conditions were still insufficient in terms of the range of 
adaptable heteroaromatic structures. Another CuBr/CsF combination system (conditions C) 
also provided a result similar to conditions B using an increased amount of the phosphine. 
Thus, pyridine and the related heteroaromatic compounds still remained as less reactive 
substrates. Consequently, the problem was overcome by replacing the DMF solvent with N-
methyl-2-pyrolidinone (NMP). It is of interest that such a solvent effect was not observed for 
the CuCl/K2CO3 combination system, but appeared for the CuBr/CsF reaction system 
(Table 3, Entry 2), giving 2-methylpyridine (2-picoline, 12d) in 81% yield. The other solvents, 
except for the amide–type solvent and amine additives, were not effective (Table 3, Entries 
4–11). Thus, the reaction in NMP at 60–100°C for 5 min using the CH3I/11a–
i/Pd2(dba)3/P(o-CH3C6H4)3/CuBr/CsF (1:40:0.5:16:2:5) combination (conditions D) gave the 
methylated products 12a–i in >80% yields (based on the reaction of CH3I) for all of the 
heteroaromatic compounds listed in this study (Table 2, Entries 1–9). Thus the combined use 
of NMP and increased amount of the bulky arenylphosphine is important to efficiently 
promote the reaction. The conditions using a Pd{P(tert-C4H9)3}2/CsF system in NMP 
reported by G. C. Fu et al. (Littke et al., 2002) were not effective by producing only a poor 
yield (21%, Table 3, Entry 2) as judged by the methylation of 2-pyridyltributylstannane 
(11d). The addition of CuBr to this system improved the yield to only a small extent (39%). 
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Entrya Heteroarenyl 
stannane 
Methylated product Yield (%)b 
Ac Bc Cc Dc 
1 
 11a 12a
28 75 73 80 
2 
11b 12b
57 87 91 94 
3 
11c 12c
52 88 90 94 
4 
11d 12d
16 
(14)d
67 63 81 
5 
11e 12e
25 
(53)e 61 66 80 
6 
11f 12f
79 60 68 87 
7 
11g 12g
3 50 48 
62 
(87)f 
8 
11h 12h
25 72 70 90 
9 
11i 12i
12 83 75 83 
aReaction was carried out with CH3I (10 mol), stannane 11 (400 mol), and Pd0 (10 mol). bThe 
products were identified by GLC analyses and comparison with authentic samples. Yields were 
determined by GLC based on CH3I consumption using n-nonane and n-heptane as internal standards, 
and are the average of 2 or 3 runs. cReaction conditions (molar ratio): A: CH3I/11/Pd2(dba)3/P(o-
CH3C6H4)3/CuCl/K2CO3 (1:40:0.5:2:2:2) in DMF at 60 °C for 5 min; B: CH3I/11/Pd2(dba)3/P(o-
CH3C6H4)3/CuCl/K2CO3 (1:40:0.5:16:2:5) in DMF at 60°C for 5 min; C: CH3I/11/Pd2(dba)3/P(o-
CH3C6H4)3/CuBr/CsF (1:40:0.5:16:2:5) in DMF at 60 °C for 5 min; D: CH3I/11/Pd2(dba)3/P(o-
CH3C6H4)3/CuBr/CsF (1:40:0.5:16:2:5) in NMP at 60 °C for 5 min. dCH3I/11d/Pd2(dba)3/P(o-CH3C6H4)3 
(1:40:0.5:2) in DMF at 120 °C for 5 min (stepwise procedure) (Iida et al, 2004). eCH3I/11e/Pd2(dba)3/P(o-
CH3C6H4)3/CuCl/K2CO3 (1:40:0.5:2:2:2) in DMF at 80 °C for 3 min (Prabhakaran et al, 2005). fThe 
reaction was conducted at 100 °C. 
Table 2. General rapid C–methylation on various neutral and basic heteroaromatic rings. 
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Entrya Solvent Additive (equiv) Yield (%)b 
CuCl/K2CO3 
synergic system 
CuBr/CsF 
synergic system 
1 DMF — 67 65 
2 NMP — 66 81 (21)c (39)d 
3 DMA — — 69 
4 DMI — — 18 
5 toluene — — 20 
6 THF — — 38 
7 DMSO — — 23 
8 HMPA — — 34 
9 DMF 2,6-lutidine (17) — 19 
10 DMF Triethylamine (14) — 20 
11 DMF DABCO (18) — 6 
aReaction was carried out with CH3I (10 mol), stannane 11d (400 mol), and Pd0 (10 mol). Reaction 
conditions (molar ratio): CH3I/11d/Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 (1:40:0.5:16:2:2) or 
CH3I/11d/Pd2(dba)3/P(o-CH3C6H4)3/CuBr/CsF (1:40:0.5:16:2:5) at 60°C for 5 min. bYield (%) of 12d was 
determined by GLC analyses based on CH3I consumption using n-heptane as the internal standard. 
cFu’s original conditions (Littke et al., 2002) (molar ratio): CH3I/11d/Pd{P(tert-C4H9)3}2/CsF (1:40:1:2). 
dFu’s original conditions + CuBr (molar ratio): CH3I/11d/Pd{P(tert-C4H9)3}2/CuBr/CsF (1:40:1:2:5). 
NMP: N-methyl-2-pyrrolidinone; DMA: N,N-dimethylacetamide; DMI: 1,3-dimethylimidazolidin-2-one; 
THF: tetrahydrofuran; HMPA: hexamethylphosphoric triamide; DABCO: 1,4-diazabicyclo[2.2.2]octane. 
Table 3. Effect of a solvent and additives in increased phosphine and synergic systems on 
the rapid trapping of methyl iodide with 2-pyridyltributylstannane (11d) to give 2-
methylpyridine (12d). 
The utility of the general rapid methylation was well demonstrated by the syntheses of the 
actual PET tracers, the 2- and 3-[11C]methylpyridines ([11C]12d and e), using Pd2(dba)3/P(o-
CH3C6H4)3/CuBr/CsF (1:16:2:5) in NMP at 60°C for 5 min, giving the desired products in 88 
and 91% radio–HPLC analytical yields (definition: (radioactivity of desired product on 
HPLC)/(total radioactivity of distributed materials on HPLC) x 100%; it means reaction 
efficiency), respectively (Figure 5) (Suzuki et al., 2009). 
(S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152, or referred 
to as H-1152P, 13) is known as the most potent, specific, and membrane–permeable inhibitor 
of small G protein Rho-associated kinase (Rho–kinase). A 11C–labeled H-1152 as a novel PET 
probe for imaging Rho-kinases was efficiently synthesized for the first time based on the 
Pd0–mediated rapid C–[11C]methylation for trifluoroacetyl (TFA)–protected 
heteroarenylstannane precursor using [11C]CH3I followed by rapid deprotection of the TFA 
group (Suzuki et al., 2011a). Thus, the C-[11C]methylation on the isoquinoline derivative was 
CH3I
N Sn(n-C4H9)3 N CH3
Pd2(dba)3
P(o-CH3C6H4)3
DMF or other solvents
 (1 mL)
60 C, 5 min
11d 12d
Additives
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performed using Pd2(dba)3/P(o-CH3C6H4)3/CuBr/CsF (1:16:2:5 in molar ratio) in NMP at 80 
°C for 5 min and the deprotection of TFA proceeded using 2 M NaOH at 25–50 °C for 1 min, 
giving [11C]H-1152 ([11C]13) with 86 ± 4% (n = 3) radio–HPLC analytical yield. The isolated 
total radioactivity was 3.8 ± 1.2 GBq (n = 3) with the radiochemical yield of 63 ± 14% (n = 3) 
(decay–corrected, based on [11C]CH3I). Both chemical and radiochemical purities were 
>99%. The total synthesis time was 38 min. The specific radioactivity at the end of the 
formation was 97 ± 10 GBq mol–1 (n = 3). The use of [11C]13 for molecular imaging studies 
of cardiovascular diseases is now in progress. 
 
Red carbon in the structure means a radionuclide. 
Fig. 5. Syntheses of 2- and 3-[11C]methylpyridines ([11C]12d, e). 
8.2 Efficient syntheses of [methyl–11C]thymidine and 4’-[methyl–11C]thiothymidine 
[18F]FLT has been developed as a more specific tumor imaging agent than [18F]FDG 
(Grierson et al., 1997, as cited in Bading & Shields, 2008). This pyrimidine analogue lacking a 
hydroxy group at C–3’ is phosphorylated by thymidine kinase 1 (TK1) and trapped in cancer 
cell. The TK1 activity increases almost 10–fold during the DNA synthesis, and thus, the 
imaging reflects the cell proliferation differentiating tumor from inflammation (Lee et al., 
2009). The first human imaging study was conducted with 1-(2’-deoxy-2’-[18F]fluoro-1--D-
arabinofuranosyl)thymine ([18F]FMAU) (Sun et al., 2005, as cited in Bading & Shields, 2008), 
showing that the tumors in the brain, prostate, thorax, and bone could be clearly visualized. 
However, there is the primary limitation in the use of [11C]- or [18F]FMAU which is being a 
relatively poor substrate for TK1 and a relatively good substrate for TK2, probably 
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accounting for its localization in the mitochondrion–rich human myocardium. On the other 
hand, 4’-thiothymine (15b), which resembles the biological properties of thymidine (15a) 
with a higher stability for the phosphorylase cleavage, underwent the 11CH3–labeling for the 
tumor imaging using a rat, exhibited a higher potential as an attractive PET probe than 
[18F]FLT (Toyohara et al., 2008). Although the PET imaging studies using various kinds of 
11C– and 18F–labeled thymidne analogues have been extensively continued, it is still difficult 
to synthesize the labeled compounds.  
Thus, we applied the rapid C–[11C]methylation of a heteroarenylstannane (see the section 
8.1) to the synthesis of the 11C–labeled thymidine and its thio–analogue (Koyama et al., 
2011). 1-(2’-Deoxy-2’-fluoro--D-arabinofuranosyl)-[methyl–11C]thymine ([11C]FMAU) and 
4’-[methyl–11C]thiothymine ([11C]15b) have so far been labeled by 11C using 5-trimethyl 
and/or tributylstannyl precursors via the Stille–type cross–coupling reaction with 
[11C]methyl iodide (Samuelsson & Långström, 2003; Toyohara et al., 2008). However, as 
anticipated, the previously reported conditions had fewer effects on the syntheses of 5-
tributylstannyl-2’-deoxyuridine (14a) and -4’-thio-2’-deoxyuridine (14b) using 
Pd2(dba)3/P(o-CH3C6H4)3 (1:4 in molar ratio) at 130 °C for 5 min in DMF, giving the desired 
products 15a and b in only 32 and 30% yields, respectively (Table 4, Entries 1 and 4). 
Therefore, we tried to adapt the current reaction conditions, including the synergic systems 
developed in our laboratory, for such heteroaromatic compounds. First, the reaction using 
CH3I/14a/Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 (1:25:1:32:2:5) at 80 °C gave thymidine 
(15a) in 85% yield (Entry 2). Whereas, CH3I/14a/Pd2(dba)3/P(o-CH3C6H4)3/CuBr/CsF 
(1:25:1:32:2:5) including another CuBr/CsF system promoted the reaction at a milder 
temperature (60 °C), giving 15a in quantitative yield (Entry 3). The chemo–response of the 
thiothymidine–precursor 14b was different from the thymidine system 14a. The optimized 
conditions obtained for 14a including the CuBr/CsF system gave 4’-thiothymidine (15b) in 
only 40% yield (Table 4, Entry 5). The reaction using 5–fold amounts of CuBr/CsF at 80 °C 
gave 15b in a much higher yield (83%, Entry 6), but unexpectedly, the reaction was 
accompanied by a large amount of an undesired destannylated product. It was considered 
that the destannylated product 17 would have been produced by proton transfer to the 
transmetallated Cu intermediate 16 from 14bCu2 with the enhanced acidity by CuI 
coordination of a sulfur atom in the thiothymidine structure (Figure 6). As expected, such a 
destannylation was significantly suppressed by changing the medium to a much more basic 
system, in which the stannyl substrate 14b would be changed to the deprotonated 18. Thus, 
the conditions CH3I/14b/Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 (1:25:1:32:2:5) at 80 °C 
gave 15b in nearly quantitative yield (98%, Table 4, Entry 7). 
 
N
R
SO2
N
HN
13: R = CH3, H-1152
[11C]13: R = [11C]CH3, [11C]H-1152
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Entrya X P(o-CH3C6H4)3 
(equiv) 
CuI, base (mol ratio) Yield (%)b 
Temp. (°C) 
60 80 100 130 
1c O 4 none 0 — — 32 
2 O 32 CuCl, K2CO3 (2:5) 67 85 — — 
3 O 32 CuBr, CsF (2:5) 100 — 97 — 
4 S 4 none — — — 30 
5 S 32 CuBr, CsF (2:5) 40 — — — 
6 S 32 CuBr, CsF (10:25) 64 83 — — 
7 S 32 CuCl, K2CO3 (2:5) 83 98 — — 
aX = O: reaction was carried out with CH3I (2.0 mol), stannane 14a (50 mol) and Pd0 (4.0 mol). X = S: 
reaction was carried out with CH3I (1.0 mol), stannane 14b (25 mol) and Pd0 (2.0 mol). bThe yield 
was determined by GLC based on CH3I consumption using acridine as the internal standard. cReaction 
was carried out with 5 equiv. of 14a relative to methyl iodide. 
Table 4. Synthesis of thymidine (15a) and 4’-thiothymidine (15b) by the rapid trapping of 
methyl iodide with 5-tributylstannyl-2’-deoxyuridine (14a) and 5-tributylstannyl-4’-thio-2’-
deoxyuridine (14b). 
 
Fig. 6. Assumed equilibration formed in the presence of a CuI salt. 
Each optimized condition obtained for 14a and b was successfully used for the syntheses of the 
corresponding PET probes with 87 and 93% radio–HPLC analytical yields (Figure 7) (Koyama 
et al., 2011). The [11C]compounds were isolated by preparative HPLC after the reaction was 
X
HO
OH
N
NH
CH3I +
O
O
(n-C4H9)3Sn Pd2(dba)3P(o-CH3C6H4)3
CuI, base
DMF, 5 min X
HO
OH
N
NH
O
O
H3C
14a: X = O
14b: X = S
15a: X = O
15b: X = S
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conducted under slightly improved conditions using a half–amount of phosphine (16 equiv) to 
give 45 and 42–59% isolated yields (decay–corrected, based on the radioactivity of [11C]CH3I 
trapped in the Pd solution). The total synthesis time was 42 min in each case until the 
radiopharmaceutical formulation, exhibiting the isolated radioactivity of 3.7–3.8 GBq and the 
specific radioactivity of 89–200 GBq mol–1 with both a chemical purity of ≥98% and 
radiochemical purity of ≥99.5% sufficient for both of animal and human PET studies (Koyama 
et al., 2011). We are currently in the process of applying these synthetic procedures to the PET 
probe syntheses according to the Guideline of Good Manufacturing Practice (GMP). 
 
(A) 
 
(B) 
 
(C) 
Fig. 7. Synthetic scheme of [methyl–11C]thymidine ([11C]15a) and 4'-[methyl–11C]thiothymidine 
([11C]15b) for a PET study (A), and the HPLC chart for the analysis of [11C]15a, b (B and C, 
respectively, radioactivity and UV vs. time). The peaks at the retention times of 7.6 and 7.4 min 
labeled B and C are [11C]15a and b, respectively. For the HPLC chart after the isolation of 
[11C]15a and b, see supporting information in the ref. Koyama et al., 2011. 
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9. Rapid C–[11C]methylation of alkenes: Rapid C–methylation of alkenes 
(rapid coupling between sp2(alkenyl)–sp3 hybridized carbons) 
The rapid C–[11C]methylation of stannyl alkene structures provides methylalkene structures, 
which are frequently observed in various biologically significant compounds such as 
retinoids, vitamin K2, squalene, and other isoprenoids, which are important for cancer 
chemotherapy. In the process of optimizing the rapid C–methylation conditions using 
twelve types of non–functional and functional 1-alkenyltributylstannanes as model 
compounds 19a–l (él), we developed four types of reaction conditions, A–D, that proceeded 
in DMF at 60 °C for 5 min (Table 5) (Hosoya et al., 2006). Among these, reaction conditions 
B: CH3I/19a–l/Pd2(dba)3/P(o-CH3C6H4)3/CuX (X = Br or Cl)/K2CO3 (molar ratio, 
1:40:0.5:4:2:5) worked well on various alkenyl stannanes rather than the previously 
developed conditions A: CH3I/19a–l/Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 (molar ratio, 
1:40:0.5:2:2:2). In addition, conditions D consisting of CH3I/19a–l/Pd2(dba)3/P(o-
CH3C6H4)3/CuX (X = Br, Cl, or I)/CsF (molar ratio, 1:40:0.5:2:2:5) showed the best results 
from the viewpoint of general applicability, affording the corresponding methylated 
compounds 20a–l in 90% or greater yields (for the consumption of methyl iodide) (Hosoya 
et al., 2006). The high efficiency of the reaction is presumably due to the synergic effect of 
the CuI salt and the fluoride anion to promote the Sn to Cu transmetallation and the 
formation of coordinatively unsaturated Pd complexes formed by a bulky arenylphosphine. 
Under conditions C using P(tert-C4H9)2(CH3), the yield was lower than that for conditions D 
using P(o-CH3C6H4)3, particularly against ǂ,ǃ-unsaturated carbonyl substrates 
(alkenyltributylstannanes 19i–l in Table 5, Entries 9–12). In this context, the reactions using 
the Pd0 complex, {(-allyl)PdCl}2/3P(tert-C4H9)2(CH3), (CH3)4NF, 3-Å molecular sieves 
(Menzel & Fu, 2003), PdCl2/2P(tert-C4H9)3, CuI, and CsF (Mee et al., 2004) gave the desired 
compound in only the same 2% yields, as judged by the reaction of 1-
cyclohexenyltributylstannane (19e). Furthermore, the stereo isomerization of a double bond 
under our conditions did not occur at all under these reaction conditions.  
 
 
Entrya 1-Alkenyltributylstannane 
19 
Yield 
of 20b
Entrya 1-Alkenyltributylstannane 19 Yield 
of 20b 
1 
19a 
98 7 
19g 
99 
2 
19b
99 8 
19h 
89 
(91)c 
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Entrya 1-Alkenyltributylstannane 
19 
Yield 
of 20b
Entrya 1-Alkenyltributylstannane 19 Yield 
of 20b 
3 
19c
83 
(88)c 
9 
19i 
85 
(96)c 
4 
19d 
84 
(89)c 10 
19j 
86 
(93)c 
5 
19e 
99 11 
19k 
95 
6 
19f 
99 12d 
19l 
84 
(91)c 
aReactions were carried out under conditions D using CH3I (10 mol), stannane 19a–l (400 mol), 
Pd2(dba)3 (5 mol), P(o-CH3C6H4)3 (20 mol), CuBr (20 mol), and CsF (50 mol). For the results under 
conditions A, B, and C, see ref. Hosoya et al., 2006. bThe products were identified by GLC analyses and 
comparison to authentic samples. The yields were determined by GLC based on CH3I. cModified 
conditions: Pd2(dba)3/P(o-CH3C6H4)3/CuBr/CsF (1:8:4:10 in molar ratio). dThe reaction using the 
conditions B: Pd2(dba)3/P(o-CH3C6H4)3/CuCl/K2CO3 (1:8:4:10 in molar ratio) gave 20l in 71% yield. 
Table 5. Rapid C–methylation on alkenyl structures. 
The utility of the rapid methylation of an alkene was well demonstrated by the synthesis of 
a 11C–labeled partial retinoid derivative [11C]20l using reaction conditions B or D (X = Br), to 
produce in the high yield of 85% (radio–HPLC analytical yield) for both conditions (Figure 
8) (Hosoya et al., 2006, see also section 11.4). 
 
 
 
(A) 
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(B) 
Fig. 8. Synthetic scheme of 11C–labeled retinoid derivative [11C]20l (A), and radio-HPLC 
chart in the analysis of the reaction mixture (B). 
10. Rapid C–[11C]methylation of alkynes 
10.1 Rapid C–methylation of alkynes (rapid coupling between sp-sp3 hybridized 
carbons) 
We set up a model reaction using methyl iodide and an excess amount of 1-
hexynyltributylstannane (21) (CH3I/21 = 1:40) with the reaction time fixed at 5 min 
(Figure 9) (Hosoya et al., 2004). The reaction with Pd{P(C6H5)3}4 gave the desired 2-
heptyne (22) in a poor yield. The previous conditions, Pd2(dba)3/P(o-
CH3C6H4)3/CuCl/K2CO3, established for the sp2(arenyl)–sp3 rapid methylation, were also 
not applicable for this reaction. Based on the screenings of the phosphine ligand and 
additives, we found that the bulky and strong –electron–donating ligand, P(tert-C4H9)3, 
facilitates the methylation (Hosoya et al., 2004). The combinations with fluoride ions, such 
as CsF or KF, were extremely efficient in promoting the reaction in a high yield. As a 
consequence, the reaction in the presence of bis(tri-tert-butylphosphine)palladium(0) 
(Pd{P(tert-C4H9)3}2) and KF in DMF at 60 °C for 5 min resulted in forming 22 in 95% yield 
(Hosoya et al., 2004).  
 
Fig. 9. Rapid coupling of methyl iodide with 1-hexynyltributylstannane (21). 
The reaction was applicable to various kinds of functionalized alkynylstannanes including 
the stannyl precursors 23 and 24, which are the substrates with steroid and 
deoxyribonucleoside frameworks, giving methylated compounds 25 and 26 in 87 and 74% 
yields, respectively (Hosoya et al., 2004). 
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10.2 Synthesis of [11C]iloprost methyl ester  
Iloprost (27) is a stable prostacyclin (PGI2) analogue specific for the PGI2 receptor, IP1, in 
peripheral systems used as a potential therapeutic agent (Skuballa & Vorbrüggen, 1981), 
having the structure of 1-propynyl on the –side chain. According to the method 
established in the previous section, the 11C–labeled iloprost methyl ester ([11C]29) was 
synthesized using [11C]CH3I and a stannyl precursor 28 in up to 72% radio–HPLC analytical 
yield. The optimization of the synthesis of [11C]29 is currently in progress. 
11. Rapid C–methylations using organoborons as trapping nucleophiles 
In general, organoboron compounds are less toxic than organostannanes. Therefore, we 
intended to elaborate the rapid C–methylation based on the Suzuki–Miyaura coupling 
reaction (Miyaura & Suzuki, 1995) as a complementary method to the Stille–type rapid C–
methylation. In this context, the Merck group reported the syntheses of [11C]toluene 
derivatives by the reaction using [11C]methyl iodide and an excess amount of arenylboron in 
the presence of PdCl2(dppf) (dppf = 1,1'-bis(diphenylphosphino)ferrocene) and K3PO4 in 
DMF under microwave heating at high temperature (Hostetler et al., 2005). In contrast, we 
intended to establish a more efficient method by moderate thermal conditions based on the 
use of a Pd0 complex without using microwaves in view of the careful treatment of a 
radiolabeled compound, and eventually, succeeded in developing very mild practical 
reaction conditions thus able to avoid the fear of an accidental radiation exposure (Doi et al., 
2009).  
11.1 Pd0–mediated rapid C–methylations by coupling reaction of methyl iodide and a 
large excess arenyl- or alkenyl boronic acid ester 
By keeping an actual PET–probe synthesis in mind, we set up the model reaction using 
methyl iodide and an excess amount of phenylboronic acid pinacol ester (30) (CH3I/30 = 
1:40) with the short reaction time fixed at 5 min (Doi et al., 2009). The results are 
summarized in Table 6. We first attempted the known conditions frequently used for a  
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Entrya Pd0 complex Ligand (L) Pd:L 
(mol ratio)
Additivesb Solvent Yield of 
2 (%)c 
1 Pd{P(C6H5)3}4 — 
— K2CO3 
1,4-
dioxane 39 
2 PdCl2{P(C6H5)3}2 — 
— K3PO4 
DME/H2
O (9:1) 24 
3 PdCl2(dppf)·CH2
Cl2 
— — K3PO4 
DME/H2
O (9:1) 
28 
4 Pd2(dba)3 
P(o-
CH3C6H4)3 
1:2 K2CO3 DMF 91 
5 Pd2(dba)3 
P(o-
CH3C6H4)3 
1:2 
K2CO3 
DMF/H2
O (9:1) 94 
6 Pd2(dba)3 
P(o-
CH3C6H4)3 
1:2 Cs2CO3 DMF 92 
7 Pd2(dba)3 
P(o-
CH3C6H4)3 
1:2 K3PO4 DMF 87 
8 Pd2(dba)3 
P(o-
CH3C6H4)3 
1:2 
CuCl/K2CO3 DMF 81 
9 Pd2(dba)3 
P(o-
CH3C6H4)3 
1:2 KF DMF 81 
aReaction was carried out with CH3I (10 mol) and 30 (400 mol), Pd0 (10 mol). b20 mol of the additive 
was used. cThe yield was determined by GLC based on CH3I. dppf: 1,1’-
bis(diphenylphosphino)ferrocene. 
Table 6. Rapid cross–coupling of methyl iodide with phenylboronic acid pinacol ester (30). 
Suzuki–Miyaura coupling reaction (Miyaura & Suzuki, 1995), but such conditions did not 
give any satisfactory results (24–39% yields; Table 6, Entries 1–3). Therefore, we attempted 
the use of a Pd0 complex coordinated with the bulky phosphine in a non–volatile solvent 
with a high polarity inspired by our successful studies on the Pd0–mediated rapid C–
[11C]methylations using organostannanes (Suzuki et al., 1997; Hosoya et al., 2004; Hosoya et 
al., 2006; Suzuki et al., 2009). As expected, the reaction was dramatically accelerated by the 
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use of the tri-o-tolylphosphine complex in DMF in the presence of K2CO3, K2CO3/H2O, 
Cs2CO3, or K3PO4 to give the desired toluene in 87–94% yields (Table 6, Entries 4–7). 
The rapid coupling reaction of methyl iodide and 30 probably proceeded via several steps 
(Eqs. (1)–(5); Doi et al., 2009) as exemplified by the presence of K2CO3 or K2CO3/H2O; 
   
the oxidative addition of methyl iodide to the Pd0 species to generate the methyl–PdII iodide 
3 (Eq. (1)); the formation of a boronate complex 32 with a high polarity boron–carbon bond 
by the coordination of a base, such as KCO3– or OH–, in a mixed system of K2CO3/H2O (Eq. 
(2)); and the substitution of 3 with 32 to afford the [PdII(methyl)(phenyl)] complex 6 and the 
unstable borate K+[B(pin)(OZ)(I)]– (33; Z = COOK or H) (Eq. (3)). The latter would be further 
converted to the more stable borate, K+[B(pin)(OZ)2] – (34), and KI (Eq. (4)). Finally, the 
reductive elimination from 6 gives the desired toluene (2) (Eq. (5)). 
The conditions were found to be versatile for various arenyl, alkenyl, and hetero–aromatic 
ring substituted borons (Doi et al., 2009). Thus, the reactions with of both arenylborons with 
both electron–donating and electron–withdrawing groups on their aromatic rings and 
hetero–aromatic, ring–substituted boron compounds smoothly proceeded under the 
conditions of CH3I/boron/Pd2(dba)3/P(o-CH3C6H4)3/K2CO3 (1:40:0.5:2:2) in DMF at 60 °C 
for 5 min, gave the corresponding methylation products in 80–99% yields. The conditions 
were also applied to the rapid C–methylation of various types of alkenyl compounds, giving 
the corresponding methylalkenes in 86–99% yields. The E and Z stereoisomers gave the 
corresponding methylated products with the retention of stereochemistry, which confirmed 
that the reaction proceeded in a completely stereocontrolled manner. 
Boronic acid and the more lipophilic esters showed the same reactivity as the pinacol 
boronate, making the labeled probe purification easier (Doi et al., 2009).   
The actual [11C]methylation using the above–mentioned conditions (Table 6, Entry 4) was 
well demonstrated in the synthesis of the [11C]p-xylene (Figure 10). Thus, the reaction of the 
[11C]methyl iodide with pinacol tolylboronate 35 gave the [11C]p-xylene ([11C]36) in 96% 
radio–HPLC analytical yield. For the rapid C–[11C]methylation, K2CO3 was more effective 
than KF or CsF. 
CH3I+ [Pd{P(o-CH3C6H4)3}2]
+ K2CO3 (or KOH)
+
+ [Pd{P(o-CH3C6H4)3}]
[Pd(CH3)I{P(o-CH3C6H4)3}]
3
31
6
toluene (2)
[Pd(CH3)(C6H5){P(o-CH3C6H4)3}]
6
CH3–C6H5
P(o-CH3C6H4)3
C6H5Bpin
3 +
K+[(C6H5)B(pin)(OZ)]
–
Z = COOK or H
32
32 K+
33
+
34
K2CO3 (or KOH) KI
[B(pin)(OZ)(I)]–
33 + K+[B(pin)(OZ)2]
– +
(1)
(2)
(3)
(5)
(4)
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(A) 
 
(B) 
Fig. 10. Synthetic scheme of 11C–labeled p-xylene ([11C]36) by rapid C–[11C]methylation 
using pinacol tolylboronate (35) (A), and radio-HPLC chart in the analysis of the reaction 
mixture (B). 
11.2 Efficient synthesis of [11C]celecoxib and its metabolites, [11C]SC-62807 
Celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide, 
38) is a selective cyclooxygenase (COX)-2 inhibitor that has analgesic and anti-inflammatory 
effects in patients with rheumatoid arthritis, but has no effect on the COX-1 activity at 
therapeutic plasma concentrations. In humans, celecoxib is extensively metabolized in the 
liver via sequential two–step oxidative pathways, initially to a hydroxymethyl metabolite 
(SC-60613), and upon subsequent further oxidation to a carboxylic acid metabolite (SC-
62807, 39). The majority of celecoxib is excreted into the bile as SC-62807. In this context, Wu 
et al. reported that SC-62807 is a substrate of drug transporters, such as OATP1B1 and 
BCRP, which presumably mediate its hepatobiliary transport. Therefore, celecoxib or SC-
62807 radiolabeled with a short–lived positron–emitting radionuclide could be a potential 
PET probe for evaluating the function of these drug transporters in hepatobiliary excretion 
(Takashima-Hirano et al., 2011). 
The synthesis of [11C]celecoxib ([11C]38) was achieved in one–pot by reacting [11C]methyl 
iodide with an excess amount of the corresponding pinacol borate precursor 37 using 
Pd2(dba)3/P(o-CH3C6H4)3/K2CO3 (1:4:9 in molar ratio) at 65 °C for 4 min in DMF (Figures 
11A and B) according to the method established in a previous section in 55 ± 30% (n = 5) 
radio–HPLC analytical yield. The isolated radiochemical yield of [11C]38 was 63 ± 23% (n 
= 7) (decay–corrected, based on [11C]CH3I) with a specific radioactivity of 83 ± 23 GBq 
mol–1 (n = 7) (Takashima-Hirano et al., 2011). The average synthesis time including 
formulation was 30 min with >99% and >98% radiochemical and chemical purities, 
respectively. [11C]SC-62807 ([11C]39) was also synthesized from the purified [11C]38 by 
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further rapid oxidation in the presence of an excess amount of KMnO4 under microwave 
irradiation (Figures 11A and C) with an 87 ± 5% (n = 3) radio–HPLC analytical yield. The 
isolated radiochemical yield of [11C]39 was 55 ± 9% (n = 3) (decay-corrected, based on 
[11C]38) and a specific radioactivity of 39 ± 4 GBq mol–1 (n = 3). The average time of 
synthesis including formulation was 20 min and produced a >99% radiochemically pure 
product. Now, the synthesis of [11C]39 was conducted using an automated sequential 
radiolabeling system equipped with microwave irradiation from the boron precursor 37. 
There, nine operations from the [11C]CH3I production to the formation of [11C]39 were 
smoothly done automatically. PET studies in rats and the metabolite analyses of 
[11C]celecoxib and [11C]SC-62807 showed mostly different excretion processes between 
these compounds, and consequently, [11C]SC-62807 was rapidly excreted via hepatobiliary 
excretion without further metabolism (Figure 11D), and therefore evaluated that it has a 
high potential as a PET probe suitable to investigate the hepatobiliary transport 
(Takashima-Hirano et al., 2011). 
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F3C
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S NH2
OO
O
O
[11C]CH3I
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P(o-CH3C6H4)3
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isolated yield (decay–corrected): [11C]38: 63 ± 23% (n = 7); [11C]39: 55 ± 9% (n = 3) 
radiochemical purity: [11C]38: >99%; [11C]39: >99%
chemical purity ( = 254 nm): [11C]38: >98%; [11C]39: >99%
synthesis time: [11C]38: 30 min; [11C]39: 20 min
specific radioactivity: [11C]38: 83 ± 23 GBq mol–1 (n = 7); [11C]39: 39 ± 4 GBq mol–1 (n = 3)
[11C]38
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Fig. 11. Synthetic scheme of [11C]celecoxib ([11C]38) and [11C]SC-62807 ([11C]39) (A), the 
HPLC chart for the analysis of [11C]38 (B) and [11C]39 (C), and the time profiles of activity in 
the blood (red point), liver (yellow pont), kidney (pink point), bile (blue point), and urinary 
bladder (light blue point) determined by PET imaging and blood sampling over 60–min 
period after administration of [11C]SC-62807 ([11C]39) to male Sprague–Dawley rats (D). The 
peak at a retention time of 9.6 min labeled B is [11C]38 and the peak at a retention time of 4.4 
min labeled C is [11C]39. UV absorbance: 254 nm.  
11.3 Efficient synthesis of 11C–incorporated acromelic acid analogue 
Acromelic acid A (Figure 12), a minor constituent isolated from Clitocybe acromelalga, 
induces allodynia in mice by intrathecal (i.t.) administration. If we can identify the receptor 
involved in the induction of allodynia, it may provide a trigger to develop novel analgesic 
drugs for use in the treatment of neuropathic pain. In this context, we have synthesized a 
novel 11C–labeled PET probe [11C]41, which was designed based on the 
(phenylthio)pyrrolidine derivative 41 that can competitively block the acromelic acid–
induced allodynia (Kanazawa et al., 2011). A protocol in which the Pd0–mediated rapid 
methylation of the pinacol borate precursor 40 with [11C]CH3I using Pd2(dba)3, P(o-
CH3C6H4)3, and K2CO3 in DMF and the following deprotection of the TFA–protected amino 
acid moiety and hydrolysis of methyl esters were successively performed in one–pot within 
5 min (4 and 1 min each) was established for the synthesis of a PET probe [11C]41 with > 99% 
of both radiochemical and chemical purities (Kanazawa et al., 2011). The isolated yield was 
34–43% (decay–corrected, based on trapped [11C]CH3I). The obtained radioactivity of [11C]41 
after an injectable formulation under the nomal conditions was 5.0–6.0 GBq and the specific 
radioactivity was 70–100 GBq mol–1 (Figure 12). The total synthesis time of [11C]41 was 
within 30 min (Figure 12). 
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Fig. 12. Efficient synthesis of 11C–labeled acromelic acid analogue [11C]41. 
11.4 Synthesis of [11C]all-trans-retinoic acid 
Retinoids are a class of chemical compounds including both naturally dietary vitamin A 
(retinol) metabolites and active synthetic analogs (Germain et al., 2006). Both experimental 
and clinical studies have revealed that retinoids regulate a wide variety of essential 
biological processes, such as vertebrate embryonic morphogenesis and organogenesis, cell 
growth arrest, differentiation, apoptosis, and homeostasis, as well as their disorders. The all-
trans-retinoic acid (ATRA), the most potent biologically active metabolite of retinol, has been 
used in the treatment of acute promyelocytic leukemia. In this context, we focused on the 
11C–labeling of ATRA. The Pd0–mediated rapid C-[11C]methylation using pinacol borate 
precursor 42 was successfully applied to the synthesis of [11C]ATRA ([11C]43) (Suzuki et al., 
2011b). The labeling reaction was conducted using [11C]CH3I in the presence of Pd2(dba)3, 
P(o-CH3C6H4)3, and Na ascorbate (1:4:9) in DMF–H2O at 65 °C for 4 min followed by basic 
hydrolysis of the methyl (at 65 °C) and ethyl ester (at 100 °C) for 2 min, to afford the desired 
[11C]43 in 36% radio–HPLC analytical yield (Figure 13). The isolated radioactivity was 1.5 
GBq with >99% and 97% radiochemical and chemical purities, respectively. The isolated 
radiochemical yield was 25% (decay–corrected, based on [11C]CH3I). Total synthesis time  
 
Fig. 13. Synthesis of 11C–labeled all-trans-retinoic acid ([11C]ATRA, [11C]43). 
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including HPLC purification and formulation was 35 min. The decomposition of the 
product has not been observed at 90 min after the end of the synthesis in the presence of 
sodium ascorbate as judged by the conservation of radiochemical purity >99%. 
12. Rapid C–[11C]methylation of alkanes  
12.1 Rapid C–[11C]methylation (rapid coupling sp3–sp3 hybridized carbons) 
The development of the fourth target of the rapid C–[11C]methylations (rapid methylation of 
an alkane framework) (see Figure 2) by the coupling between sp3–sp3 carbons using 11CH3I 
and organoborons is also currently underway using a similar procedure in our group. 
12.2 Another rapid coupling between sp3–sp3 hybridized carbons: Efficient synthesis 
of [11C]NSAIDs and these esters 
In order to perform the in vivo molecular imaging of cyclooxygenases (COXs), well–known 
as key enzymes in prostaglandin biosynthesis, we intended to develop a novel method to 
rapidly incorporate a 11C radionuclide into various 2-arenylpropionic acids that have a 
common methylated structure, particularly abundant among nonsteroidal anti-
inflammatory drugs (NSAIDs). Consequently, we elaborated the rapid 11C–labeling using 
the reaction of [11C]CH3I and an enolate intermediate generated from the corresponding 
ester under basic conditions, followed by the one–pot hydrolysis to convert it into the 11C–
incorporated acid as [11C]NSAID (Figure 14A) (Takashima-Hirano et al., 2010b). Methoxy 2-
arenylpropionate is much less polar due to the increase in hydrophobicity of an introduced 
methyl group and the less hyperconjugation between the C–H bond of the benzylic 
position and C=O *, which is also possible for the LUMO (*) of a phenyl moiety, allowing 
easy separation of the desired 11C–labeled product from the demethylated compound. This 
method is quite general and utilized for the syntheses of the following six PET probes of 
NSAIDs: [11C]ibuprofen ([11C]50), [11C]naproxen ([11C]51), [11C]flurbiprofen ([11C]52), 
[11C]fenoprofen ([11C]53), [11C]ketoprofen ([11C]54), [11C]loxoprofen ([11C]55), and their 
corresponding esters as racemates ([11C]44–49), with sufficient radioactivity (1.7–5.5 GBq) for 
animal and human PET studies. The isolated radiochemical yields (decay–corrected) based 
on [11C]CH3I of [11C]44–55 were 26–76%. Notably, we found that methyl esters were 
particularly useful as pro-radioprobes for the study of neuroinflammation in the brain. The 
microPET studies of rats with lipopolysaccharide (LPS)–induced brain inflammation clearly 
showed that the radioactivity of the PET probes, [11C]ketoprofen methyl ester ([11C]48) and 
[11C]ketoprofen ([11C]54) specifically accumulated in the inflamed region (Figure 14B), 
giving the first successful example of the in vivo molecular imaging of neuroinflammation 
by the noninvasive PET technology. A metabolite analysis in the rat brain revealed that the 
intravenously administrated methyl ester was initially taken up in the brain and then 
underwent hydrolysis to form a pharmacologically active form of the corresponding acids. 
Hence, we succeeded in the general 11C–labeling of 2-arenylpropionic acids and their methyl 
esters as PET probes of NSAIDs to construct a potentially useful PET–probe library for the in 
vivo imaging of inflammation involved in the COX expression (Shukuri et al., 2011). The 
above racemic NSADs are readily separated by a chiral column to give an optically pure 
compound. Tetrabutylammonium fluoride (TBAF) was also effective to promote the rapid 
[11C]methylation of the enolate in THF as found in our (Takashima-Hirano et al., 2010a) and 
other group (Kato et al., 2010). The [11C]methylation of an analogous enolate has been 
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applied to the synthesis of 11C–labeled -aminoisobutyric acid as a PET probe for cancer 
imaging (Kato et al., 2011).  
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Fig. 14. Synthesis of 11C–labeled 2-arylpropionoc acids and their esters (A), and PET images of 
[11C]ketoprofen methyl ester ([11C]48, left panel) and [11C]ketoprofen ([11C]54, right panel) in 
rat brain inflammation induced by lipopolysaccharide injection into the left striatum (B). Left 
PET image showed high accumulation in the area of inflammation, indicating that the methyl 
ester penetrated the blood–brain barrier and underwent hydrolysis in the brain to produce 
carboxylic acid as a pharmacologically active form, accumulating the inflammation area. 
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13. Opportunity for the rapid C–[18F]fluoromethylation (rapid  
18F–incorporation into an organic framework through the carbon–carbon 
bond forming reaction) 
13.1 Rapid C–fluoromethylations 
The C–[11C]methylation is associated with C–[18F]fluoromethylation by a similar coupling 
methodology using [18F]fluoromethyl bromide ([18F]FCH2Br) and [18F]fluoromethyl iodide 
([18F]FCH2I) as the available 18F–labeling precursor for the synthesis of various types of PET 
tracers by N- or O-[18F]fluoromethylation (Zhang & Suzuki, 2007). There are many benefits 
based on the success of the 18F–labeling by rapid C–[18F]fluoromethylation: (1) capability of a 
relatively long in vivo study complementary to 11C, (2) feasible delivery of 18F–labeled probes 
to distant PET centers and clinics, (3) insertion of multi–reactions after labeling, and (4) the 
use as a prosthetic group in click chemistry for the labeling of peptides, nucleic acids, 
sugars, etc. The application of rapid 18F–labeling to biologically significant organic 
compounds will be reported in due course. 
Initially, we investigated the Pd0–mediated rapid cross–coupling using non-radioactive 
fluoromethyl iodide and phenyltributylstannane or a boron compound prior to the actual 
C–[18F]fluoromethylation (Doi et al., 2009). The conditions for rapid C–methylation using an 
organoboron in Table 6, Entry 4, were efficient for the synthesis of the fluoromethyl arene. 
Furthermore, a slightly improved condition using the 1:3 ratio of Pd0/P(o-CH3C6H4)3 was 
found to be the most effective for promoting the fluoromethylation with pinacol 
phenylboronate 30, giving the desired benzyl fluoride in 57% yield (Doi et al., 2009). Thus, 
the conditions using FCH2I for the synthesis of an [18F]fluoromethyl–labeled PET probe was 
established. 
13.2 Rapid C–[18F]fluoromethylation 
We set up the reaction using ca. 0.5 GBq of [18F]FCH2X (X = Br or I) and a 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid methyl ester (56) (Figure 15). First, we 
found that the labeling reaction using [18F]FCH2I and 56 for 5 min at 65 °C gave the desired 
p-([18F]fluoromethyl)benzoic acid methyl ester ([18F]57) using Pd2(dba)3/P(o-CH3C6H5)3 (1:6) 
and K2CO3 in DMF. The radio–HPLC analytical yield of [18F]57 was 23 %, but a considerable 
amount of side products with a high polarity appeared, which might be the [18F]fluoride ion 
derived from the decomposition of [18F]FCH2I. However, to the best of our knowledge, this 
result was the first evidence for the Pd0–mediated rapid C–[18F]fluoromethylation. After a 
broader investigation of not only labeling chemistry, but also the mechanical operations of 
our radiolabeling system, we concluded that the C–[18F]fluoromethylation with [18F]FCH2Br 
will be more practical than that with [18F]FCH2I. Actually, [18F]FCH2I was essentially more 
reactive to the Pd0 complex, but [18F]FCH2I was not stable and gradually decomposed in the 
light–exposed solution. For these reasons, we then focused on developing the C–
[18F]fluoromethylation using [18F]FCH2Br. The reaction was dramatically promoted under 
the conditions of 120 °C for 5 and 15 min in DMPU/H2O (9:1) to give [18F]57 in 48 and 64% 
yields, respectively. HPLC analyses showed that the reaction for 5 min resulted in the 
unreacted [18F]FCH2Br remaining to a considerable extent, but the reaction for 15 min 
produced a remarkably sharp peak of [18F]57 as the main product. The C–
[18F]fluoromethylation would be completed within 15 min because the reaction for 30 min 
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did not produce a further increase in the yield. The 15–min reaction thus obtained matches 
well with the 18F–incorporated PET–probe synthesis because of the longer half–life (110 min) 
of the 18F radionuclide compared to 11C (20.4 min) (Doi et al., 2010). 
 
Fig. 15. Rapid C–[18F]fluoromethylation using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzoic acid methyl ester (56) under PET radiolabeling conditions. 
14. Conclusions 
In this chapter, a ground–braking methodology based on the use of cutting–edge chemistry 
was introduced for the synthesis of a short–lived 11C–incorporated PET tracer. First, a 
general method for the rapid reaction of methyl iodide with an arenyltributylstannane 
(excess amount) (the Stille–type reaction) was established, producing a methylarene in the 
presence of the bulky tri-o-tolylphosphine–bound coordinatively unsaturated Pd0 complex, 
a CuI salt, and K2CO3 based on a synergic effect to promote the reaction. The reaction was 
used for the synthesis of the 15R-[11C]TIC methyl ester as an actual PET probe. The rapid C–
methylation was expanded to other types of rapid methylations including the methylation 
on heteroaromatic frameworks by adding another CuI/CsF synergy and choosing the bulky 
trialkylphosphine for the alkene and alkyne, thus allowing the radio synthesis of various 
biologically and clinically important molecules. To meet the further demands of an efficient 
labeling method in PET, we established a rapid methylation using methyl iodide and an 
organoboron compound (Suzuki–Miyaura type coupling) as a complementary trapping 
substrate to an organostannane in the presence of Pd0, tri-o-tolylphosphine, and K2CO3 or 
K2CO3/H2O in high yield. The reaction conditions were also applied to the C–
fluoromethylation, and, after slight modifications, we realized the incorporation of the 
rather longer half–lived 18F radionuclide into organic frameworks (rapid C-
[18F]fluoromethylation). Our five original papers (Suzuki et al., 2009; Doi et al., 2009; Hosoya 
et al., 2006; Koyama et al., 2011; Hosoya et al., 2004, in order for ranking) were ranked Nos. 
1–5 among the top 10 articles published in the same domain in BioMedLib (search engine for 
the 20 million articles of MEDLINE, April 2009–June 2011). Accordingly, a “Bible” on the 
syntheses of 11C– and 18F–labeled compounds has been continuously updated to provide 
valuable information required for a PET chemist.  
As shown in Figure 16, RIKEN CMIS has utilized three types of remote–controlled 
synthesizers for 11C– and 18F–labeling, which originally developed with the focus on 
synthetic organic chemistry. 
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(A) (B) (C) 
Fig. 16. Our original remote–controlled synthesizer for 11C– and 18F–labeling; H19D: an early 
type system hybridized by septum–cannula and robot–arm method for the solution transfer 
(A), H20S: the improved model for step–wise labeling operations (B), and H20J: standard 
model focused on the simplicity and operational stability of the remote controlled synthetic 
procedures (C). 
The next step is the application of the descrived synthetic procedure for the synthesis along 
with the Guidance of Good Manufacturing Practice (GMP) regulation. We also consider that 
the rapid reactions using a microfluidic system (microreactor) will be important in order to 
reduce the amount of a substrate (if scarce or very expensive) without lengtheing the 
reaction time. 
The methods thus described have widely been applied by other groups to synthesize 11C–
labeled PET probes, such as N,N-dimethyl-2-(2-amino-4-[11C]methylphenylthio)benzylamine 
(MADAM, [11C]58, Tarkiainen et al., 2001), the serotonin transporter inhibitor, 5-[11C]methyl-6-
nitroquipazine ([11C]59, Sandell et al., 2002), [11C]toluene ([11C]2, Gerasimov et al., 2002), the 
central nicotinic acetylcholine inhibitor, 3-[(2S)-azetidin-2-ylmethoxy]-5-[11C]methylpyridine 
([11C]60, Karimi & Långström, 2002; Iida et al., 2004), [11C]FMAU ([11C]61, Samuelsson & 
Långström, 2003), the serotonin reuptake inhibitor, citalopram analogue, [5-methyl-11C]{3-[1-
(4-fluorophenyl)-5-methyl-1,3-dihydroisobenzofuran-1-yl]-propyl}-dimethylamine ([11C]62, 
Madsen et al., 2003), the adrenergic neurotransmitter, 4-[11C]methylmetaraminol ([11C]63, 
Langer et al., 2003), the metabotropic glutamate 1 antagonist, (3-ethyl-2-[11C]methyl-6-
quinolinyl)-(cis-4-methoxycyclohexyl)methanone ([11C]64, Huang et al., 2005), the COX-2 
selective inhibitor and prescription drug, [11C]celecoxib ([11C]38, Prabhakaran et al., 2005), (+)-
p-[11C]methylvesamicol for mapping sigma1 receptors ([11C]65, Ishiwata et al., 2006), the NK–3 
receptor antagonist, [11C]SB 222200 ([11C]66, Bennacef et al., 2007), the reboxetin analogues 
([11C]67 and [11C]68, Zeng et al., 2009), the derivative of the selective 7 nicotinic acetylcholine 
receptor partial agonist, 4-[11C]methylphenyl 2,5-diazabicyclo[3.2.2]nonane-2-carboxylate 
([11C]CHIBA-1001, [11C]69, Toyohara et al., 2009), [11C]-aminoisobutyric acid for cancer 
imaging ([11C]70), etc.  
15. Perspectives 
Molecular imaging with PET is the only method for elucidating the whole–body 
pharmacokinetics of molecules in humans. This technique could be adapted for the efficient 
screening of drug candidates in humans during the early stage of the drug development 
process (phase 0 as a pre-clinical trial), and accelerating the path leading to clinical trials, 
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resulting in revolutionizing drug development. The chemistry covering a broad range of 
designs, syntheses, and labelings is expected to play a central role in this interdisciplinary 
scientific field. 
The objective of the study was to develop a novel chemical methodology for in vivo 
molecular imaging adaptable from animals to humans. As already described, we developed 
various types of rapid C–[11C]methylations and C–[18F]fluoromethylations by the Pd0–
mediated cross–coupling reactions between [11C]methyl iodide or [18F]fluoromethyl idodide 
(or bromide) and organostannanes or organoborons, respectively, for the synthesis of short–
lived PET molecular probes. The synthesis method would also be applicable for the 
incorporation of other carbon isotope units, such as CH218F, 13CH3, 14CH3, CD3, and CH219F, 
allowing the application to accelerator mass spectrometry (AMS) and MRI. In particular, 
PET and AMS using 11C and 14C (use of 10–20 M), respectively, are two methods capable of 
promoting a human microdose study under political regulations (Europe, 2004; U.S., 2006; 
Japan, 2008).  
 
We intend to further expand the rapid C–[11C]methylations and [18F]fluoromethylations and 
their applications in order to construct a library of 11C– and 18F–incorporated biologically 
significant molecules involved in various diseases important for medical treatment, such as 
cerebral diseases (Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic laterals 
sclerosis (ALS), etc.), cardiovascular diseases (hypertention, stroke, glaucoma, etc.), cancer, 
diabetes, infection (human immunodeficiency virus (HIV), hepatitis C virus (HCV), 
influenza, prion, etc.), inflammation, neuropathic pain, and transporter dysfunction, as a 
frontier research to promote in vivo molecular science.  
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In an advanced medical field, tailor–made medicine, personalized medicine based on single 
nucleotide polymorphism, and evidence–based medicine based on PK/PD studies in 
humans are emphasized by the rapid progress of genome science. We believe that the 
advancement of “in vivo molecular science in humans” is strongly required in order to 
achieve the medical objectives. The progress of in vivo human molecular science will serve to 
overcome the “Death Valley” existing between a preclinical study and the clinical trials in 
the drug development process in order to revolutionize disease diagnosis and the drug 
discovery process. 
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